FDA approves Ketyruda/Inlyta in 1L-RCC: https://finance.yahoo.com/news/fda-approves-merck-keytruda-pembrolizumab-104500869.html The RCC battle lines are set: Opdivo/Yervoy vs Keytruda/Inlyta.